Small Business Innovation Research · Small Business Technology Transfer
Angion Biomedica Corp.: SBIR & STTR awards
77 awards worth $60.96M to 1 companies since 1999 match these filters. Phase I tests an idea (usually a few hundred thousand dollars); Phase II builds it (often $1M or more).
Angion Biomedica Corp.'s federal contracts and grants · All SBIR & STTR awards
Awards by year
| Year | Phase I | Phase II | Amount |
|---|---|---|---|
| 2019 | 1 | 0 | $220.7K |
| 2017 | 2 | 0 | $442.2K |
| 2016 | 0 | 1 | $1.32M |
| 2014 | 2 | 1 | $1.29M |
| 2013 | 2 | 0 | $632.0K |
| 2012 | 3 | 4 | $8.90M |
| 2011 | 1 | 3 | $4.42M |
| 2010 | 7 | 1 | $4.90M |
| 2009 | 3 | 7 | $15.41M |
| 2008 | 7 | 1 | $3.77M |
| 2007 | 6 | 2 | $3.25M |
| 2006 | 1 | 3 | $5.68M |
The latest year fills in over months: agencies report awards to SBIR.gov with a lag.
Latest matching awards
| Award | Company | Agency | Phase | Amount | Date |
|---|---|---|---|---|---|
| Targeted Therapeutics for Liver Disease · topic 300 | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $220.7K | 2019-04-01 |
| Steroid β hydroxylase inhibitor for Cushing s Syndrome · topic 200 | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $222.7K | 2017-09-15 |
| ROCK selective inhibitor for Chronic Kidney Disease · topic 300 | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $219.5K | 2017-09-15 |
| Aldosterone Synthase Inhibitor for CKD · topic 400 | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.32M | 2016-04-01 |
| PDGFR and KDR Inhibitors for Liver Fibrosis · topic NIDDK | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $770.0K | 2014 |
| A Therapeutic for Radiation Induced Lung Injury · topic NIAID | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $299.9K | 2014 |
| A Novel Small Molecule Therapeutic for Alcoholic Chronic Pancreatitis · topic NIAAA | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $224.3K | 2014 |
| Aldosterone Synthase Inhibitor for CKD · topic NIDDK | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $380.9K | 2013 |
| A collagen wound dressing augmented with a proteoglycan mimic to enhance chronic · topic NIAAA | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $251.0K | 2013 |
| Anti-Fibrotic Therapy for Scleroderma/SSc · topic NIAMS | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.81M | 2012 |
| A Novel Therapeutic for Liver Fibrosis · topic NIAAA | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.09M | 2012 |
| Antifibrotic Therapy for Chronic Kidney Disease · topic NIDDK | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.78M | 2012 |
| Novel Neuroprotective/Restorative Therapy for Ischemic Stroke · topic NINDS | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.19M | 2012 |
| An Innovative Cardioprotective · topic NHLBI | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $373.9K | 2012 |
| LPA Antagonists for the Treatment of IPF · topic NHLBI | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $354.1K | 2012 |
| Retinoic Acid Modulation for Scleroderma · topic NIAMS | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $298.1K | 2012 |
| Treatment for alcoholic liver disease · topic NIAAA | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.05M | 2011 |
| Unique Clinical Study on DGF Using Paired Kidneys · topic NIDDK | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.34M | 2011 |
| Phase I Clinical Study Using an Antifibrotic Drug · topic NIDDK | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $764.6K | 2011 |
| A Novel Therapeutic for Liver Fibrosis · topic NIAAA | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $269.2K | 2011 |
| A Pilot Clinical Study in Acute STEMI · topic NHLBI | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.91M | 2010 |
| A Novel Therapeutic for Chronic Kidney Disease · topic NIDDK | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $391.3K | 2010 |
| Phase I Clinical Study Using an Antifibrotic Drug · topic NIDDK | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $311.3K | 2010 |
| Anti-Fibrotic Therapy for Scleroderma/SSc · topic NIAMS | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $287.6K | 2010 |
| Antifibrotic Therapy for Chronic Kidney Disease · topic NIDDK | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $271.9K | 2010 |
| PDGFR and KDR Inhibitors for Liver Fibrosis · topic NIDDK | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $269.8K | 2010 |
| Treatment for alcoholic liver disease · topic NIAAA | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $238.5K | 2010 |
| Therapeutic Potential of PARP inhibitor for Acute Pancreatitis · topic NIDDK | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $219.1K | 2010 |
| Safety and PK Study in Hepatic Impairment Patients | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.98M | 2009 |
| Novel Neuroprotective/Restorative Therapy for Ischemic Stroke | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.30M | 2009 |
| Novel Neuroprotective/Anti-inflammatory Therapy for Ischemic Stroke | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.18M | 2009 |
| Therapeutic use of small-molecule HGF-mimetic for emphysema | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.09M | 2009 |
| Small Molecule Therapeutics for Renal Disease | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.94M | 2009 |
| Pilot Clinical Study in Renal Transplantation | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.66M | 2009 |
| Novel Therapy for Amyotrophic Lateral Sclerosis | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $1.45M | 2009 |
| Novel therapeutic for Alcoholic Liver Disease | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $327.3K | 2009 |
| Phase I Study of BB3 in Dialysis Patients | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $290.6K | 2009 |
| Novel Therapeutic for Duchenne Muscular Dystrophy (DMD) | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $200.5K | 2009 |
| Refanalin for lung preservation and transplantation | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase II | $2.08M | 2008 |
| Phase I Clinical Trial for BB3 | Angion Biomedica Corp. · California | Department of Health and Human Services · National Institutes of Health | SBIR Phase I | $295.5K | 2008 |
Source: SBIR.gov award data (SBA) ↗, awards through 2026-08-28. Amounts are as agencies report them to SBA. SBIR/STTR contracts also appear in USAspending as ordinary awards; grants (NIH, NSF, DOE) appear as assistance. Open topics are posted by each agency; see Opportunities for contract notices.